Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.
about
Recent clinical trials of cancer immunogene therapy in companion animals.P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions.Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.Vaccine and immune cell therapy in non-small cell lung cancer.
P2860
Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Safety and efficacy of p62 DNA ...... ts with advanced solid tumors.
@en
type
label
Safety and efficacy of p62 DNA ...... ts with advanced solid tumors.
@en
prefLabel
Safety and efficacy of p62 DNA ...... ts with advanced solid tumors.
@en
P2093
P2860
P356
P1433
P1476
Safety and efficacy of p62 DNA ...... ts with advanced solid tumors.
@en
P2093
Albert A Sufianov
Alexander M Shneider
Alexandr V Zyryanov
Anatoly F Tsyb
Andrey B Komissarov
Andrey Chursov
Basile N Oshchepkov
Dmitry M Ponomarenko
Elena V Filippova
Franco Venanzi
P2860
P304
53730-53739
P356
10.18632/ONCOTARGET.16574
P407
P577
2017-03-25T00:00:00Z